Artiva Biotherapeutics Showcases AlloNK Data at EULAR 2026
SAN DIEGO, California, May 19, 2026 Artiva Biotherapeutics announced multiple data presentations at the upcoming EULAR 2026 Congress highlighting...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SAN DIEGO, California, May 19, 2026 Artiva Biotherapeutics announced multiple data presentations at the upcoming EULAR 2026 Congress highlighting...
San Diego, California, January 21, 2026 — Artiva Biotherapeutics, a clinical-stage biopharmaceutical company focused on allogeneic natural killer (AlloNK)...
